<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015144</url>
  </required_header>
  <id_info>
    <org_study_id>502-11-585</org_study_id>
    <nct_id>NCT01015144</nct_id>
  </id_info>
  <brief_title>The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle</brief_title>
  <official_title>The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess of the influence of atorvastatin on selected indicators of
      an inflammatory condition, function of the left ventricle and factors affecting the
      occurrence of undesired events like rehospitalizations and mortality in patients with dilated
      cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No statin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tulip</intervention_name>
    <description>Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood68
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with dilated cardiomyopathy (according ESC 2007) with EF≤40% as documented by
        echocardiography were included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 18 years old or older

          -  patients who signed informed consent

          -  patients with dilated cardiomyopathy (according ESC 2007)

          -  patients who had no significant coronary artery stenoses &gt;30% on cardiac
             catheterization

        Exclusion Criteria:

          -  BP ≥140/90 lub &lt;90/60

          -  congenital heart disease

          -  acquired valvular disease except for mitral incompetence secondary to left ventricular
             dilatation

          -  New York Heart Association (NYHA) functional class IV

          -  statin treatment

          -  preserved hyperactivity of aminotransferases with unexplained etiology,

          -  muscle disorders which might cause drug-induced myopathy,

          -  uncontrolled diabetes,

          -  liver diseases,

          -  creatinine level &gt; 2 mg/dl and/or GFR&lt;30ml/min,

          -  abuse of alcohol or drugs,

          -  chronic inflammatory diseases,

          -  pregnancy or lactation,

          -  severe hypothyroidism,

          -  immunosuppressive treatment,

          -  operation or severe injury during last month

          -  vaccination during last 3 months

          -  heart stimulation device or implantable cardioverter defibrillator

          -  or who didn't write conscious consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agata Bielecka-Dabrowa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hypertension UM Lodz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maciej Banach, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hypertension UM Lodz</affiliation>
  </overall_official>
  <reference>
    <citation>Bielecka-Dabrowa A, Wierzbicka M, Dabrowa M, Goch A. New methods in laboratory diagnostics of dilated cardiomyopathy. Cardiol J. 2008;15(4):388-95. Review.</citation>
    <PMID>18698552</PMID>
  </reference>
  <reference>
    <citation>Bielecka-Dabrowa A, Wierzbicka M, Goch JH. [Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target]. Wiad Lek. 2007;60(9-10):433-8. Review. Polish.</citation>
    <PMID>18350717</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Agata Bielecka-Dąbrowa</name_title>
    <organization>UM Lodz</organization>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>dilated cardiomyopathy</keyword>
  <keyword>heart failure</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

